This is what I’d do about the GlaxoSmithKline share price right now

GlaxoSmithKline plc (LON: GSK) looks attractive as an income play, but is that really the case?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the past five years, the GlaxoSmithKline (LSE: GSK) share price has hardly budged. Excluding dividends, the stock has returned -4.3% since the beginning of 2014, underperforming the FTSE 100, which returned 19.8% over the same time frame.

However, when you include dividends, the picture is significantly different. Including distributions to investors over the half-decade, the GlaxoSmithKline share price has underperformed by 2.7% per annum. Over the past decade, the stock has produced a total return of 8.5% compared to 11.4% for the FTSE 100, index including dividends.

Based on this performance, it’s difficult to tell what the future holds for the GlaxoSmithKline share price. The fact that the stock has gone nowhere over the past five years doesn’t give me any confidence it will be any different over the next five.

That being said, past performance rarely dictates future returns. Just because the company’s shares have underperformed is in the past, doesn’t mean they will continue to do so. With this in mind, I’m going to try and determine what the future holds for the stock.

What does the future hold?

To figure out whether or not the GlaxoSmithKline share price is an attractive investment, it’s vital to consider why it’s underperformed in the past, and what its future holds.

Considering the group’s earnings performance over the past six years, I don’t think it’s unreasonable to say that the business has gone backwards since 2013. Indeed for 2018, the company reported a net profit of £3.6bn, down around a third in five years. This seems to explain why the GlaxoSmithKline share price has underperformed the FTSE 100 over the past five years.

But now it looks as if this trend is coming to an end. Looking at City projections, it seems as if analysts are expecting the group to report earnings growth of 24% in 2019, followed by 5.2% in 2020. If the company manages to meet these targets, it would be a vast improvement for the business. Over the past five years, earnings per share have only fallen. Analysts are expecting the firm to report a net profit of £5.6bn for 2019, which will be a six-year high if it does.

If management’s efforts to turn the business around yield concrete results this year, then I think there could be a re-rating of the shares. At the time of writing, shares in the pharmaceutical group are changing hands as a forward P/E of just 13.5, that’s below the global pharmaceutical industry average of 18.

To put it another way, the GlaxoSmithKline share price seems to be undervalued by approximately 30% compared to its international peers.

The bottom line

Considering this valuation gap, and after factoring in the City’s growth projections for 2019, I think it could be worth buying the GlaxoSmithKline share price right now.

If the company does manage to return to growth over the next 12 months, I think the stock deserves to trade at a much higher valuation. Investors buying today can also pocket a 5.3% dividend yield while they wait for the recovery to take shape.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »